- Home
- BMRN vs BXP Comparison
BMRN vs BXP Comparison
Compare BMRN & BXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | BXP |
|---|---|---|
| Founded | 1996 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 11.5B |
| IPO Year | 1999 | 1997 |
Fundamental Metrics
Financial Performance| Metric | BMRN | BXP |
|---|---|---|
| Price | $53.19 | $69.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 18 |
| Target Price | ★ $88.42 | $77.78 |
| AVG Volume (30 Days) | ★ 3.0M | 1.3M |
| Earning Date | 10-27-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 4.04% |
| EPS Growth | ★ 59.53 | N/A |
| EPS | ★ 2.68 | N/A |
| Revenue | $3,094,001,000.00 | ★ $3,425,025,000.00 |
| Revenue This Year | $13.39 | $3.60 |
| Revenue Next Year | $7.57 | $1.60 |
| P/E Ratio | $19.92 | ★ N/A |
| Revenue Growth | ★ 12.39 | 2.42 |
| 52 Week Low | $50.76 | $54.22 |
| 52 Week High | $73.51 | $83.29 |
Technical Indicators
Market Signals| Indicator | BMRN | BXP |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 40.64 |
| Support Level | $53.03 | $71.22 |
| Resistance Level | $54.66 | $72.50 |
| Average True Range (ATR) | 1.45 | 1.52 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 31.61 | 16.88 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.